Business
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
SAN DIEGO, March 04, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today initiated patient dosing in its exploratory PIPE-791 Phase 1b, randomized, double-blind, placebo-controlled, crossover, chronic pain trial. PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid
About this update from Contineum Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1875,"height":663,"url":"https://media.zenfs.com/en/business-wire.com/5a0d4b4080c234009477decb4ef0f8f3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tygb9qdqNEujOe1tEBN2ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMzOTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5a0d4b4080c234009477decb4ef0f8f3","width":960,"height":339},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/hIBbhDNAtk8_c1WzNaFS9w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5a0d4b4080c234009477decb4ef0f8f3","width":1200,"height":424}},"lazy":false},{"type":"text","content":"- Exploratory phase 1b trial will evaluate safety, tolerability and effect on pain intensity- Topline data readout planned for early 2026","length":138,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, March 04, 2025--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today initiated patient dosing in its exploratory PIPE-791 Phase 1b, randomized, double-blind, placebo-controlled, crossover, chronic pain trial. PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R).","length":540,"tagName":"p"},{"type":"text","content":"PIPE-791 is being evaluated for the treatment of chronic pain associated with two separate indications, osteoarthritis (OA) and low back pain (LBP). The Company expects to enroll approximately 40 patients at up to five sites in the U.S., and a treatment duration of 28 days. Contineum anticipates topline data from the PIPE-791 Phase 1b chronic pain trial in early 2026.","length":370,"tagName":"p"},{"type":"text","content":""With its unique mechanistic action, PIPE-791 has the potential to modify the maladaptive changes associated with chronic pain," said Stephen Huhn, Chief Medical Officer, Contineum Therapeutics. "This trial was designed to inform our decision-making on further advancing the chronic pain program. We’re excited for the prospect that PIPE-791 may provide a potentially differentiated,...